{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T23:16:59Z","timestamp":1768691819498,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.08.026","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T15:38:16Z","timestamp":1725377896000},"page":"102512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The use of concomitant medications on nephrotoxicity associated with teicoplanin: A retrospective observational study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-0357","authenticated-orcid":false,"given":"Yuki","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-5589","authenticated-orcid":false,"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1550-1460","authenticated-orcid":false,"given":"Takeaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoka","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Komasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.08.026_bib1","first-page":"833","article-title":"Teicoplanin","volume":"79","author":"Shea","year":"1995","journal-title":"Med Clin"},{"key":"10.1016\/j.jiac.2024.08.026_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin","volume":"37","author":"Wood","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007022.pub2","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jiac.2024.08.026_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.33.1.82","article-title":"Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers","volume":"33","author":"Carver","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl D","key":"10.1016\/j.jiac.2024.08.026_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/jac\/14.suppl_D.43","article-title":"Pharmacokinetics of vancomycin","volume":"14","author":"Moellering","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib6","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: a systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.08.026_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3390\/pharmaceutics14030489","article-title":"Clinical practice guidelines for therapeutic drug monitoring of vancomycin in the framework of model-informed precision dosing: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2024.08.026_bib8","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bcpt.13679","article-title":"Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression","volume":"130","author":"Hirai","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.jiac.2024.08.026_bib9","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/jac\/dkab499","article-title":"Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring","volume":"77","author":"Hanai","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00544566","article-title":"Binding of teicoplanin to human serum albumin","volume":"33","author":"Assandri","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.08.026_bib11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkx473","article-title":"Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy","volume":"73","author":"Byrne","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0b013e3180690755","article-title":"Variability in teicoplanin protein binding and its prediction using serum albumin concentrations","volume":"29","author":"Yano","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2024.08.026_bib13","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2024.08.026_bib14","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.3748\/wjg.v27.i26.3984","article-title":"Acute kidney injury and hepatorenal syndrome in cirrhosis","volume":"27","author":"Gupta","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jiac.2024.08.026_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1091581819831701","article-title":"Kidney pathophysiology, toxicology, and drug-induced injury in drug development","volume":"38","author":"Radi","year":"2019","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.jiac.2024.08.026_bib16","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1097\/CCM.0b013e318168c92f","article-title":"Oliguria, volume overload, and loop diuretics","volume":"36","author":"Bagshaw","year":"2008","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2024.08.026_bib17","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/jps.2600730738","article-title":"Plasma protein binding of warfarin: methodological considerations","volume":"73","author":"Mungall","year":"1984","journal-title":"J Pharmaceut Sci"},{"key":"10.1016\/j.jiac.2024.08.026_bib18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00003495-198325020-00002","article-title":"Calcium antagonists. Pharmacokinetic properties","volume":"25","author":"Kates","year":"1983","journal-title":"Drugs"},{"key":"10.1016\/j.jiac.2024.08.026_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2165\/00003088-199222010-00003","article-title":"Clinical pharmacokinetics of amlodipine","volume":"22","author":"Meredith","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2024.08.026_bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"10.1016\/j.jiac.2024.08.026_bib21","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40262-015-0326-7","article-title":"The first-in-class potassium-competitive acid blocker, vonoprazan fumarate: pharmacokinetic and pharmacodynamic considerations","volume":"55","author":"Echizen","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2024.08.026_bib23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jiac.2024.08.026_bib24","first-page":"157","article-title":"Comparison between teicoplanin and vancomycin in the occurrence of adverse events in patients whose trough concentration was \u226720 \u03bcg\/mL","volume":"6","author":"Takubo","year":"2013","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","article-title":"High-dose regimen to achieve novel target trough concentration in teicoplanin","volume":"20","author":"Ueda","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-41095-4","article-title":"Drug\u2013drug interaction signals between loop diuretics and teicoplanin during acute kidney injury evaluated using Japanese spontaneous adverse drug event reports","volume":"13","author":"Hirai","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2024.08.026_bib28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/20.5.697","article-title":"Teicoplanin: renal tolerance and pharmacokinetics in rats","volume":"20","author":"Marre","year":"1987","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib29","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/phar.2388","article-title":"Vancomycin-induced kidney injury: animal models of toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention","volume":"40","author":"Pais","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2024.08.026_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1378\/chest.126.2.534","article-title":"Renal effects of norepinephrine in septic and nonseptic patients","volume":"126","author":"Alban\u00e8se","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2024.08.026_bib31","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccc.2020.11.010","article-title":"Sepsis-associated acute kidney injury","volume":"37","author":"Manrique-Caballero","year":"2021","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jiac.2024.08.026_bib32","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/dkaa458","article-title":"Nephrotoxicity of teicoplanin-based combination therapy: focus on piperacillin\/tazobactam and other anti-pseudomonal \u03b2-lactams","volume":"76","author":"Tai","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/jac\/dkaa385","article-title":"Nephrotoxicity of concomitant piperacillin\/tazobactam and teicoplanin compared with monotherapy","volume":"76","author":"Workum","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib34","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2125.1994.tb04251.x","article-title":"Plasma protein binding displacement interactions--why are they still regarded as clinically important?","volume":"37","author":"Rolan","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.08.026_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02466-16","article-title":"Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy","volume":"61","author":"Byrne","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2024.08.026_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2125.1984.tb02387.x","article-title":"Plasma concentrations of unbound phenytoin in the management of epilepsy","volume":"17","author":"Kilpatrick","year":"1984","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.08.026_bib37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijantimicag.2015.03.010","article-title":"Changes in the pharmacokinetics of teicoplanin in patients with hyperglycaemic hypoalbuminaemia: impact of albumin glycosylation on the binding of teicoplanin to albumin","volume":"46","author":"Enokiya","year":"2015","journal-title":"Int J Antimicrob Agents"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:47:24Z","timestamp":1738928844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24002435"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.08.026","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use of concomitant medications on nephrotoxicity associated with teicoplanin: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.08.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102512"}}